Selections from current literature: using aspirin for primary or secondary prevention

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Aspirin is widely used for preventing thrombotic vascular events.
• Optimal dosing strategies for primary versus secondary prophylaxis remain debated.
• Balancing the benefits of aspirin against bleeding risks is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose aspirin (75 mg/day) in thrombotic event prevention.
• To compare the indications for aspirin use in primary versus secondary prophylaxis.
• To define a conservative approach for aspirin prescription.

Main Methods:

• Review of existing data on aspirin dosing for thrombotic event prevention.
• Analysis of hemorrhagic complications associated with low-dose aspirin therapy.
• Comparative assessment of benefits versus risks in primary and secondary prevention scenarios.

Main Results:

• Low-dose aspirin (75 mg/day) appears sufficient for preventing thrombotic occlusion.
• No evidence supports different aspirin doses for primary or secondary prophylaxis.
• Serious hemorrhagic complications, though small in number, are associated with aspirin use.

Conclusions:

• The benefits of aspirin in secondary prevention for high-risk individuals generally outweigh the risks.
• Primary prophylaxis with aspirin is more controversial due to less gain and higher potential harm in asymptomatic populations.
• A conservative approach recommends reserving primary aspirin prophylaxis for individuals with the highest estimated vascular risk.